http://orcid.org/0000-0002-3706-2454
References
- Chowdhury G, Shibata N, Yamazaki H, Guengerich FP. (2014). Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide. Chem Res Toxicol 27:147–56
- Elkinson S, McCormack PL. (2013). Pomalidomide: first global approval. Drugs 73:595–604
- Hasegawa M, Kawai K, Mitsui T, et al. (2011). The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 405:405–10
- Hoffmann M, Kasserra C, Reyes J, et al. (2013). Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol 71:489–501
- Jones JR, Pawlyn C, Davies FE, Morgan GJ. (2016). The safety of pomalidomide for the treatment of multiple myeloma. Expert Opin Drug Saf 15:535–47
- Kasserra C, Assaf M, Hoffmann M, et al. (2015). Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug–drug interaction potential in vitro and in healthy subjects. J Clin Pharmacol 55:168–78
- Murayama N, van Beuningen R, Suemizu H, et al. (2014). Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of pregnane X receptor. Chem Res Toxicol 27:304–8
- Nishiyama S, Suemizu H, Shibata N, et al. (2015). Simulation of human plasma concentrations of thalidomide and primary 5-hydroxylated metabolites explored with pharmacokinetic data in humanized TK-NOG mice. Chem Res Toxicol 28:2088–90
- Shida S, Utoh M, Murayama N, et al. (2015). Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Xenobiotica 45:881–6
- Shida S, Yamazaki H. (2016). Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling. Xenobiotica 46:759–64
- Utoh M, Suemizu H, Mitsui M, et al. (2016). Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica 46:1049–55
- Yamamoto T, Shibata N, Sukeguchi D, et al. (2009). Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides. Bioorg Med Chem Lett 19:3973–6
- Yamazaki H, Suemizu H, Kazuki Y, et al. (2016a). Assessment of protein binding of 5-hydroxythalidomide bioactivated in humanized mice with human P450 3A-chromosome or hepatocytes by two-dimensional electrophoresis/accelerator mass spectrometry. Chem Res Toxicol 29:1279–81
- Yamazaki H, Suemizu H, Mitsui M, et al. (2016b). Combining chimeric mice with humanized liver, mass spectrometry, and physiologically-based pharmacokinetic modeling in toxicology. Chem Res Toxicol. [Epub ahead of print]. doi: 10.1021/acs.chemrestox.6b00136
- Yamazaki H, Suemizu H, Murayama N, et al. (2013). In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice. Chem Res Toxicol 26:486–9
- Yamazaki H, Suemizu H, Shimizu M, et al. (2012). In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice. Chem Res Toxicol 25:274–6